Plasma-modified ACT can be used to monitor bivalirudin (Angiomax®) anticoagulation for on-pump cardiopulmonary bypass surgery in a patient with heparin-induced thrombocytopenia

Journal of Extra-Corporeal Technology

Volumn 36, Issue 2, 2004, Pages 174-177

  Jabr, Karim ^a   Johnson, Joe H ^a   McDonald, Miles H ^a   Walsh, Diane L ^a   Martin, William D ^a   Johnson, Anton C ^a   Pickett, John M ^a   Shantha Martin, Usha ^a  

^a MEDICAL CENTER OF CENTRAL GEORGIA   (United States)

Author keywords

Anticoagulation; Bivalirudin; Heparin induced thrombocytopenia; On pump cardiopulmonary bypass surgery; Plasma modified ACT

Indexed keywords

ANTIBODY; ARGATROBAN; HEPARIN; HEPARIN ANTIBODY; HIRULOG; LEPIRUDIN; THROMBIN INHIBITOR; UNCLASSIFIED DRUG;

ANGIOPLASTY; ANTICOAGULATION; ARTICLE; BLEEDING; BLOOD CLOTTING TIME; BOLUS INJECTION; CARDIOPULMONARY BYPASS; CONTINUOUS INFUSION; DRUG EFFICACY; DRUG ELIMINATION; DRUG INDUCED DISEASE; HEART SURGERY; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; MORBIDITY; ON PUMP CARDIOPULMONARY BYPASS SURGERY; PATIENT MONITORING; PLASMA MODIFIED ACTIVATED CLOTTING TIME; PREVALENCE; UNITED STATES;

EID: 3142674894     PISSN: 00221058     EISSN: 29698960     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Francis JL, Palmer GJ, Moroose R, et al. Comparison of bovine and porcine heparin in heparin antibody formation after cardiac surgery. Ann Thorac Surg. 2003;75:17-22.
2. Williams R, Mascelli MA, Damaraju LV, et al. Anti-platelet factor 4/heparin antibodies are a novel, independent predictor of 30-day myocardial infarction during acute coronary ischemic syndromes [abstract #106172]. http://aha.agora.com/abstractviewer/search.asp.
3. Warkentin TE. Management of heparin-induced thrombocytopenia: A critical comparison of lepirudin and argatroban. Thromb Res. 2003;110:73-82.
4. Bittl JA, Chaitman BR, Feit F, et al. Bivalirudin vs. heparin during coronary angioplasty for unstable or postinfarction angina: Final report reanalysis of the Bivalirudin Angioplasty Study. Am Heart J. 2001;142:952-9.
5. Lincoff AM, Bittl JA, Harrington RA, et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA. 2003;289:853-63.
6. Mahaffey KW, Lewis BE, Wildermann NM, et al. The anticoagulant therapy with bivalirudin to assist in the performance of percutaneous coronary intervention in patients with heparin-induced thrombocytopenia (ATBAT) study: Main results. J Invas Cardiol. 2003;15:611-6.
7. Ohteki H, Furukawa K, Ohnishi H, et al. Clinical experience of argatroban for anticoagulation in cardiovascular surgery. Jpn J Thorac Cardiovasc Surg. 2000;48:39-46.
8. Koster A, Hansen R, Kuppe H, et al. Recombinant hirudin as an alternative for anticoagulation during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II: A 1-year experience in 57 patients. J Cardiothorac Vasc Anesth. 2000;14:243-8.
9. Stafford-Smith M, Swaminathan M, McCreath BJ, et al. Morbidity-related serum creatinine patterns after coronary bypass surgery [abstract]. Anesth Analg. 2001;92(Suppl):SCA123.
10. Koster A, Kukucka M, Bach F, et al. Anticoagulation during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II and renal impairment using heparin and the glycoprotein IIb-IIIa antagonist tirofiban. Anesthesiology. 2001;94:245-51.
11. Kabbani SS, Aggarwal A, Terrien EF, et al. Suboptimal early inhibition of platelets by treatment with tirofiban and implications for coronary interventions. Am J Cardiol. 2002;89:647-50.
12. ESPRIT Investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): A randomised, placebo-controlled trial. Lancet. 2000;356:2037-44.
13. The EPISTENT Investigators. Randomized placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet. 1998;352:87-92.
14. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med. 1997;336:1689-96.
15. Weitz JI, Crowther M. Direct thrombin inhibitors. Thromb Res. 2002;106:275-84.
16. Koster A, Despotis G, Gruendel M, et al. The plasma supplemented modified activated clotting time for monitoring of heparinization during cardiopulmonary bypass: A pilot investigation. Anesth Analg. 2002;95:26-30.
17. Despotis GJ, Hogue CW, Saleem R, et al. The relationship between hirudin and activated clotting time: Implications for patients with heparin-induced thrombocytopenia undergoing cardiac surgery. Anesth Analg. 2001;93:28-32.
18. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia and cardiac surgery. Ann Thorac Surg. 2003;76:638-48.
19. Johnston N, Jessen ME, DiMaio M, et al. The emergency use of recombinant hirudin in cardiopulmonary bypass. J Extra Corpor Technol. 1999;31:211-5.
20. Merry A. Society of Cardiovascular Anesthesiologists 24th Annual Meeting, New York, NY. April 20-24, 2002. Anesth Analg 2002 [abstract];93:SCA.
21. Koster A, Chew D, Grundel M, et al. Bivalirudin monitored with the ecarin clotting time for anticoagulation during cardiopulmonary bypass. Anesth Analg. 2003;96:383-6.
22. Baker T. Bivalirudin monitored with the high dose thrombin time during cardiopulmonary bypass [abstract]. American Society of Extra-Corporeal Technology (AmSECT) 41st International Meeting, 2003. J Extra Corpor Technol. 2003;35:54.
23. The Medicines Company, personal communication.